Weigh Pros and Cons of SGLT2 Inhibitors for Kidney Protection

June 2019

You'll see more interest in using SGLT2 inhibitors (Invokana, etc) for renal protection in patients with type 2 diabetes.

Earlier findings from CV studies suggest SGLT2 inhibitors may protect the kidneys...probably by lowering intraglomerular pressure.

Now there's evidence in patients with chronic kidney disease.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote